Kristen Hege, Member Board of Directors at KSQ Therapeutics, shared on LinkedIn:
“I was deeply honored to be inducted as a Fellow into the Society for Immunotherapy of Cancer (SITC) Academy of Immunology-Oncology last night.
It was even more special to share this celebration with my husband Gibson Biddle and long time friends and colleagues Lynelle Hoch, Michael Pourdehnad, Mike Burgess, Timothy Campbell, Ashley Koegel and Rosanna Ricafort.
Equally exciting to share the honor of being the first two Biopharma inductees with Rachel W. Humphrey. It’s always the people in our lives that makes these celebrations special.”
About Kristen Hege
Kristen Hege is a physician-scientist with more than 30 years of experience in cancer research, oncology and immunotherapy. She previously held senior leadership roles at Bristol Myers Squibb and Celgene, where she was involved in the development of new cancer treatments, including Abecma, a CAR T-cell therapy for multiple myeloma. She also spent many years at UCSF as a clinical professor of medicine.
Today, she serves on the boards of several biotech companies, including KSQ Therapeutics, and remains actively involved in SITC. She was named a Fellow of the SITC Academy of Immunology-Oncology, becoming one of its first two biopharma inductees alongside Rachel W. Humphrey.
Read more articles featuring Kristen Hege on OncoDaily.